Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Mathew Thomas V, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: kohli m. Urol Pract. 2024 Jan;11(1):32-35. doi: 10.1097/UPJ.0000000000000471. Epub 2023 Oct 30. Urol Pract. 2024. PMID: 37903742
Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors.
Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, O'Neil B, Schmidt B, Dechet C, Hashibe M, Sanchez A. Dindinger-Hill K, et al. Among authors: kohli m. Clin Genitourin Cancer. 2024 Feb 17:102057. doi: 10.1016/j.clgc.2024.02.008. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38503572
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal N. Coletta AM, et al. Among authors: kohli m. BMC Cancer. 2024 Apr 18;24(1):493. doi: 10.1186/s12885-024-12260-3. BMC Cancer. 2024. PMID: 38637770 Free PMC article.
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: kohli m. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
Carthon BC, Kim SE, McDermott DF, Dutcher JP, Puligandla M, Manola J, Pins M, Carducci MA, Plimack ER, Appleman LJ, MacVicar GR, Kohli M, Kuzel TM, DiPaola RS, Haas NB. Carthon BC, et al. Among authors: kohli m. Clin Genitourin Cancer. 2023 Oct;21(5):546-554. doi: 10.1016/j.clgc.2023.06.012. Epub 2023 Jul 3. Clin Genitourin Cancer. 2023. PMID: 37455214 Clinical Trial.
553 results